TRI-611 / Triana Biomedicines - LARVOL DELTA

TRI-611, a selective, CNS-penetrant molecular glue degrader of ALK with anti-tumor activity against preclinical models of ALK-fusion positive non-small cell lung cancer including kinase inhibitor refractory tumors (AACR-NCI-EORTC 2025) - "The distinct binding interface of TRI-611 leads to broad selectivity across the global proteome including closely related kinases such as NTRK1, allowing for sustained high target coverage, including in the CNS, without the off-target liabilities that are associated with TKIs. TRI-611 is currently in IND-enabling studies with the potential to transform the treatment of ALK+ NSCLC and would represent the first clinical stage molecular glue degrader of an oncogenic fusion protein."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • NTRK1